Upstream Bio, Inc.
NASDAQ:UPBBiotechnology
+$0.10 today
- Market cap
- $114.01M
- Beta
- 1.11
- P/E (TTM)
- -2.2
- EPS (TTM)
- -$2.89
Volume 1.24M
Average 0.66M
UPB Deferred Revenue
Payments received for goods or services the company will deliver within the next year.
Upstream Bio, Inc.NASDAQ: UPB
Deferred Revenue · Q1 FY2026 · quarter ended Mar 2026
Deferred revenue remains negative
Q1 FY2026 deferred revenue was $0, compared with $0 a year earlier.
Context
- Deferred revenue amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Deferred revenue increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Deferred Revenue history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Deferred Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
Deferred Revenue vs competitors
How UPB compares with its peers on the latest reported figures
- Peers report in different currencies, so deferred revenue is compared through growth and share of total assets rather than absolute size.
- Deferred revenue amounts to 0.0% of total assets for UPB, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $88.77M USD | -18.1% | -27.7% | 8.5% | |
| Mar 2026 | $9.4M USD | -83.6% | +12.1% | 1.6% | |
| Mar 2026 | $630K USD | -97.0% | -45.0% | 0.1% | |
UPBUpstream Bio, Inc. | Mar 2026 | $0 USD | — | — | 0.0% |
| Sep 2026 | $0 USD | — | — | 0.0% | |
| Jun 2026 | $0 USD | — | — | 0.0% | |
| Sep 2026 | $0 USD | — | — | 0.0% | |
| Sep 2026 | €0 EUR | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding UPB) | — | -83.6% | -27.7% | 0.0% | |
Competitors are the stored peer set for UPB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Upstream Bio, Inc.
NASDAQ:UPB
Intrinsic Alpha fair value
Locked
Current Price
$2.08
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.